Engineering T cells with chimeric antigen receptors (CARs) is proving to be an effective method for directing T cells to attack tumors in an MHC-independent manner. Current generation CARs aim to recapitulate T cell signaling by incorporating modular functional components of the TCR and costimulatory molecules. Development of next generation CARs has relied upon trial and error evaluation of si...

Despite advances in treatment options, the clinical outcomes of pediatric patients with advanced solid tumors have hardly improved decades, and alternative options are urgently needed. Innovative therapies, such as chimeric antigen receptor (CAR) T cells oncolytic viruses (OVs), currently being evaluated both adults children refractory tumors. Because remarkably diverse biologically different f...

Abstract Chimeric antigen receptor T cells have revolutionized the treatment of hematological malignancies during past five years, boasting impressive response rates and durable remissions for patients who previously had no viable options. In this review, we provide a brief historical overview their development. We focus on practical aspects patient’s journey through unique toxicities current b...

CD8⁺cytotoxic T cells, CD4⁺ helper and regulatory cells interact differently with cancer. CD8⁺ cytotoxic recognize the antigens presented by cancer kill in various ways. recruit other immune promote them to destroy cells. On hand, suppress cell proliferation response of both This suppressive mechanism often leads progression These cell-cancer interactions can render conventional treatments inef...